Multi-Stakeholder Engagement As Key Driver of Patient- and Clinically Relevant Outcomes

Across neurological disorders, defining endpoints that reflect true patient benefit remains a major challenge. Clinicians and payers often prioritize cognition and activities of daily living as the most clinically and economically relevant outcomes, but clinical trials of existing and novel treatments rarely deliver substantial or sustained improvements in these areas. At the same time, regulators and HTA bodies increasingly call for endpoints that are both clinically meaningful and patient-relevant. In this context, early and structured engagement of multiple stakeholders, including clinicians, payers, patients, and caregivers, throughout the clinical development of neurological treatments is critical to ensuring endpoints capture outcomes that matter most in real life, both from clinical and patient standpoints.

This article describes the stakeholder groups and the valuable perspectives they can provide to companies preparing for clinical trials in neurological disorders, as well as the risks posed by a lack of engagement with these stakeholders. It also provides best practices for coordinated multi-stakeholder engagement throughout product development that help to result in not only positive trial outcomes but also successful reimbursement and adoption of much-needed treatments.

Stakeholder Perspectives on Endpoint Design and the Risks of Limited Engagement

While payers are the key to market access, companies can strengthen value narratives and future pricing and reimbursement negotiations if they integrate the voices of KOLs, clinicians, HTA bodies, patients, and caregivers throughout the clinical development of neurological treatments.

Different stakeholder groups provide varied points of view on trial endpoints:

Key opinion leaders (KOLs) and clinicians

KOLs and clinicians bring scientific and methodological expertise, ensuring measures are valid, sensitive, and feasible in trials. Biomarkers are among one of the most important clinical endpoints for clinicians in neurological disorders, but they are often not decisive for HTA bodies (especially in France and Germany), as their link to clinical effectiveness is not always rigorously demonstrated.

Payers and HTAs

Payers and HTAs determine what evidence will translate into access and reimbursement. They tend to focus on validated, standardized measures with demonstrable clinical and functional value. Precedent-based endpoints remain the cornerstone for payers and HTAs; novelty is welcomed only when clearly anchored to real-world meaning. They also focus on functional outcomes: activities of daily living, independence, and time to caregiver need. Note that functional outcomes also resonate with patients, as they represent tangible quality-of-life benefits.

Patient advocacy groups (PAGs) and caregivers

They can highlight what “meaningful benefit” actually looks like to them, e.g., independence, emotional well-being, and preserved social functioning. Digital endpoints hold promise when it comes to meaning for patients but still face acceptance barriers. Early alignment with regulators and payers can accelerate their validation. In neurological disorders, digital tools often rely on caregiver input in late-stage disease, which can unintentionally increase caregiver burden if not properly designed.

Most existing guidance on patient involvement in endpoint definition remains largely theoretical, focusing on conceptual definitions rather than establishing structured mechanisms for direct patient collaboration.

The implementation of the EU Joint Clinical Assessment marks a significant step toward harmonizing the evaluation of health technologies across Europe—and, for the first time, it formally integrates the patient perspective into a unified European framework. PAGs now have a structured role in contributing with their lived experience, helping to define outcomes that truly matter to patients and ensuring that assessments reflect real-world needs and preferences. This harmonized approach replaces the previously fragmented, country-specific patient involvement, reinforcing their voices as a cornerstone of evidence generation and decision-making at the EU level.

Risks of Limited Multi-Stakeholder Engagement

The risks of limited multi-stakeholder engagement include trial designs that fail to address real patient needs. This can lead to treatments that do not meaningfully improve daily functioning or quality of life. Another risk is that endpoints overlook true disease burden, such as fluctuating symptoms, cognitive decline, or caregiver impact. Studies may miss what matters most to patients, regulators, and payers. This increases the likelihood of regulatory or HTA pushback, including requests for additional data, delayed approvals, and weaker value dossiers.

Without early payer input, companies face poor market access, pricing challenges, and misaligned expectations about treatment benefits. Failure to engage patients, caregivers, and PAGs throughout development also reduces trust and limits opportunities to differentiate in competitive therapeutic areas. Ultimately, these gaps can restrict reimbursement, adoption, and real-world patient benefit.

Best Practices for Multi-Stakeholder Engagement

Designing patient- and clinically relevant outcomes in neurological disorders requires a coordinated, multi-stakeholder approach. When companies foster these collaborations early, they can design trials that are scientifically robust, clinically relevant, and meaningful to payers, HTA bodies, and patients, ensuring that success is shared among all stakeholders. Here are some best practices for engaging these stakeholders.

Break down silos between functions

Early collaboration between clinical, medical, and market access teams avoids late-stage redesigns or misalignment with HTA expectations. Create cross-functional working groups early in the development process to help maintain alignment between scientific innovation and value demonstration.

Include payer perspectives early

Early inclusion of payer perspectives ensures evidence generation strategies meet reimbursement and policy requirements, not just regulatory needs. Conduct regular dialogue with payers and HTA experts to guide endpoint prioritization, ensuring that evidence is robust, credible, and relevant.

Engage patients and caregivers during trial planning

Work with patients and caregivers during trial planning to surface unmet needs and anchor statistical outcomes to real-world benefit. This process requires optimal planning and time. Incorporate their insights at the design stage to help identify the most meaningful outcomes from a lived-experience perspective and enhance future acceptance of the results.

Adapt endpoints to the stage of disease

The stage of the disease plays a critical role in defining patient-relevant endpoints, especially in neurodegenerative disorders. Advancing disease may impair patients’ capacity to express their perspectives, leading to evolving definitions of meaningful outcomes and a potential loss of direct patient input.

Recognize and measure caregiver burden

Caregiver burden, while often overlooked, will likely grow in importance as new HTA frameworks evolve to consider societal and family impacts. Caregivers are often required to act as the “patient’s voice” in numerous neurological disorders, especially neurodegenerative conditions, since the condition often impairs the patient’s capacity to communicate effectively.  

Conclusion

Meaningful endpoint definition in neurological disorders depends on aligning clinical measurement with the realities patients and caregivers navigate every day. When sponsors integrate payer, HTA, clinician, and lived-experience input early, they avoid endpoints that are scientifically sound yet disconnected from functional relevance, daily fluctuations, caregiver impact, and long-term burden—factors that increasingly determine regulatory credibility and reimbursement outcomes. In neurological disorders where demonstrating meaningful benefit is historically difficult, this disciplined, inclusive approach is the most reliable path to both regulatory traction and real-world adoption.

Looking for more market access insights? Check out our collection of expert articles.